*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

**百奧賽圖(北京)醫藥科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2315)**

## INSIDE INFORMATION
## ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR 2025

This announcement is made by Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the disclosure obligations under Rule 13.09(2)(a) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company sets out in this announcement the financial data for the year of 2025. Such data are prepared in accordance with the China Accounting Standards for Business Enterprises and are preliminary accounting data only, and have not been audited by a certified public accountant. The data set out in this announcement may differ from the final data to be disclosed in the 2025 annual report of the Company. Shareholders and investors of the Company are advised to exercise caution when dealing in the shares of the Company.

## I. MAJOR FINANCIAL DATA AND INDICATORS FOR THE YEAR 2025

*Unit: RMB10,000*

| Item | The Reporting Period | Corresponding period of last year | Period-on-period change (%) |
|---|---|---|---|
| Total operating revenue | **137,880.84** | 98,045.39 | 40.63 |
| Research and development expenses | **43,805.44** | 32,392.45 | 35.23 |
| Operating profit | **18,858.04** | 4,451.02 | 323.68 |
| Total profit | **18,803.05** | 4,293.96 | 337.90 |
| Net profit attributable to owners of the Company | **17,319.98** | 3,354.18 | 416.37 |
| Net profit attributable to owners of the Company after deducting non-recurring profit or loss | **11,607.78** | 2,296.80 | 405.39 |
| Basic earnings per share (RMB) | **0.43** | 0.08 | 437.50 |
| Weighted average return on net assets | **16.85%** | 4.14% | Increased by 12.71 percentage points |

| | End of the Reporting Period | Beginning of the Reporting Period | Change (%) |
|---|---|---|---|
| Total assets | **372,436.22** | 241,531.36 | 54.20 |
| Equity attributable to owners of the Company | **217,491.14** | 83,405.88 | 160.76 |
| Share capital | **44,689.84** | 39,939.84 | 11.89 |
| Net assets per share attributable to owners of the Company (RMB) | **5.44** | 2.09 | 160.29 |

*Notes:*

1. The "Reporting Period" shall mean the year from January 1, 2025 to December 31, 2025.

2. The figures at the beginning of the Reporting Period are the same as the audited figures at the end of the previous year.

3. The above financial data and indicators are filled in with the data of the consolidated statements, but have not been audited. The final results are subject to the 2025 annual report of the Company.

## II. EXPLANATION ON OPERATING RESULTS AND FINANCIAL CONDITIONS

### (I) Operating conditions and financial conditions of the Company during the Reporting Period

1. During the Reporting Period, the Group achieved an operating revenue of RMB1,378,808,400, representing a year-on-year increase of 40.63%; achieved a net profit attributable to owners of the Company of RMB173,199,800; achieved a net profit attributable to owners of the Company after deducting non-recurring profit or loss of RMB116,077,800.

2. At the end of the Reporting Period, the total assets of the Group were RMB3,724,362,200, representing an increase of 54.20% as compared with the beginning of the period; equity attributable to owners of the Company was RMB2,174,911,400, representing an increase of 160.76% as compared with the beginning of the period.

3. Key factors affecting operating results:

   During the Reporting Period, the growth in the Group's operating results mainly benefited from the continuous expansion in overseas markets coupled with the recovery and warming up of the domestic biopharmaceutical industry, which led to a rapid growth in the Group's operating revenue. In addition, the Group steadfastly pursued an innovation-driven growth strategy, building core technological barriers through continuous high-intensity research and development investment to ensure the business remains at a high gross profit level, while lean management initiatives further enhanced operating efficiency, driving the rapid improvement of the Group's profitability.

### (II) Explanation on items with period-on-period changes exceeding 30%

The total operating revenue, research and development expenses, operating profit, total profit, net profit attributable to owners of the Company, net profit attributable to owners of the Company after deducting non-recurring profit or loss, basic earnings per share, weighted average return on net assets, total assets, equity attributable to owners of the Company, and net assets per share attributable to owners of the Company all recorded significant growth as compared with the corresponding period of last year. Such growth was mainly due to the fact that the Group achieved rapid growth in its operating results during the Reporting Period; high-intensity research and development investment was maintained to build core technological barriers, enabling the gross profit margin to remain at a high level; the Company completed its listing of A shares, with net proceeds of RMB1,144,059,300, significantly improving its capital structure.

## III. RISK WARNING

The major financial data for the year 2025 set out in this announcement are preliminary accounting data, which have not been audited by an accounting firm and may differ from the data disclosed in the 2025 annual report of the Company. The specific data shall be those disclosed in the 2025 annual report of the Company. Investors are hereby reminded of the investment risks.

By order of the Board
**Biocytogen Pharmaceuticals (Beijing) Co., Ltd.**
**Shen Yuelei**
*Chairman of the Board, Chief Executive Officer and Executive Director*

Hong Kong, February 26, 2026

*As at the date of this announcement, the board of the Company comprises Dr. Shen Yuelei as chairman, chief executive officer and executive director, Dr. Ni Jian as executive director; Mr. Liu Hongkang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive directors; and Ms. Li Yan as employee director.*